Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...

Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low dise ...

Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive ...

Organon has shared positive results from a long-term extension (LTE) study of its Vtama (tapinarof) cream, 1% in atopic ...

Today, on International Women's Day, the Society of Obstetricians and Gynaecologists of Canada (SOGC) is calling on women to ...

A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...

The Prime Minister, Justin Trudeau, today issued the following statement on International Women's Day: "Women in Canada have made transformative progress in shaping our country for the better. Today, ...

If approved, tapinarof's main rival will be Amgen and its oral PDE4 inhibitor Otezla (apremilast) – acquired for $13.4 billion in 2019 in side deal to Bristol-Myers Squibb's $74 billion takeover ...

“With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there JERSEY CITY, N.J., December 16, 2024--Organon's VTAMA (tapinarof) cream is a ...

First in class In May, the U.S. Food and Drug Administration approved Vtama (tapinarof) cream, an aryl hydrocarbon receptor agonist and the first FDA-approved steroid-free topical medication in ...

Organon has recently announced new results from the phase 3 ADORING 3 open-label, long-term extension study evaluating tapinarof cream, 1% (VTAMA), for the treatment of atopic dermatitis (AD). The ...